NASDAQ · STOCK
Novo Nordisk A/S
$49.48
52W $224.25 – $464.60
56/100
$1.43T
11.7
1.86
Price History (6M)
Executive Summary
7 analysts weighed in with 43% agreement on a bullish lean. Portfolio Manager: Portfolio position concentration is currently healthy. Risk Analyst: Current ratio of 0.80 is tight -- limited short-term liquidity cushion. Overall recommendation: WATCH.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
56/100
Agreement
43%
Analysts
7
Conviction
Contested
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ P/E of 11.6 is inexpensive for the broad market
− Price-to-book of 7.4x prices in significant intangible value
Growth Analyst
bearish
38
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bearish
35
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.80 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
55
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
65.6
Neutral
MACD Histogram
0.144
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$45.06
Resistance
$62.32
Bollinger %B
0.76
Inside Bands
Price vs Moving Averages
EMA 9
$48.77
Above
EMA 21
$47.36
Above
EMA 50
$45.51
Above
EMA 200
$49.67
Below
Fundamental Analysis
Valuation
54
Growth
60
Profitability
100
Financial Health
46
Valuation
P/E Ratio
11.7×
P/B Ratio
7.44×
PEG Ratio
—
Dividend Yield
3.65%
52W High
$464.60
52W Low
$224.25
Quality & Growth
ROE
6636.0%
ROA
2327.0%
Gross Margin
8185.0%
Operating Margin
4530.0%
Revenue Growth YoY
+813.0%
Debt / Equity
0.67
AI Fundamental Assessment
P/E ratio of 11.7 (inexpensive relative to a 15-40x range); Price-to-book of 7.4x; Revenue growth (YoY) of 8.1%; EPS growth (YoY) of 16.7%; Return on equity of 66.4%; Return on assets of 23.3%; Net margin of 37.2%; Gross margin of 81.8%; Current ratio of 0.80 (tight short-term liquidity); Debt-to-equity of 0.67; Most recent quarter beat estimates by 23.1%; 2 consecutive earnings beats; EPS growth decelerating (+34.2% -> +9.8% QoQ); Analyst estimates rising over recent quarters
Key Risks
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full NVO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile